A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

Trial Profile

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Sotagliflozin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Lexicon Pharmaceuticals
  • Most Recent Events

    • 08 Sep 2015 Results will be presented at the European Association for the Study of Diabetes 2015, according to a Lexicon Pharmaceuticals media release.
    • 06 Jun 2015 Results published in a Lexicon Pharmaceuticals media release.
    • 06 Jun 2015 According to a Lexicon Pharmaceuticals media release, data from this trial were presented at the 75th Scientific Sessions of the American Diabetes Association (ADA) as part of 4th Annual Diabetes Care Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top